Societe General, Prudential, others buy 3 per cent stake in Anthem Biosciences for Rs 1,275 cr

Global investors including Societe Generale and Prudential Hong Kong, alongside Indian mutual funds and insurance companies, have bought a 3 percent stake in Anthem Biosciences. The deal, valued at Rs 1,275 crore, saw promoter Aruna Ganesh exit the company. This significant transaction reshapes the promoter's holding in the integrated Contract Research, Development and Manufacturing Organisation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/67R3r9I
via IFTTT

Read More

Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soon

Indian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federal Trade Commission for its takeover of Lannett Company. This regulatory approval removes the final hurdle. The acquisition is expected to close by the end of June.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XzE6rDb
via IFTTT

Read More

HPV vaccination drive reaches 50 lakh girls in three months

India's free Human Papillomavirus vaccination drive is making significant progress. Nearly 50 lakh doses of the cervical cancer vaccine have been administered to 14-year-old girls. This initiative covers almost half of the 1.15 crore target population nationwide. Madhya Pradesh and Gujarat have already achieved 100% of their targets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/85l3uED
via IFTTT

Read More

US FTC imposes divestment condition on Aurobindo Pharma's $250 mn Lannett acquisition

The U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a condition for Aurobindo Pharma to finalize its acquisition of Lannett Company Inc., ensuring no anti-competitive issues arise from the deal.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u3jUDq4
via IFTTT

Read More

KKR eyes at least $1 billion stake in Medicover's India hospital arm, source says

Global investment firm KKR is in advanced discussions to acquire a significant stake in Medicover's Indian hospital operations. The deal is valued at over one billion dollars. Medicover, a Swedish healthcare group, confirmed these talks. This potential acquisition marks a substantial expansion for KKR in India's growing healthcare sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sc8UvWY
via IFTTT

Read More

API prices fall as West Asia tensions ease, boosting Indian pharma sector

Prices for active pharmaceutical ingredients have seen a decline of five to ten percent, thanks to the calming geopolitical climate in West Asia, which has brought stability to supply chains. Indian pharmaceutical manufacturers are breathing a sigh of relief as they manage to offset rising input expenses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9PFqER2
via IFTTT

Read More

Public-private projects key to expand access to Kidney care: NephroPlus

NephroPlus, India's leading provider of dialysis services, is on a mission to reshape the future of kidney health with an innovative tech-based platform aimed at preventing chronic kidney disease. As it scales up its network of dialysis centers both domestically and in global markets, this forward-thinking initiative seeks to combat the advancement of kidney ailments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Wwvfs57
via IFTTT

Read More